“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Filippo Montemurro, Laura Pizzuti et al.|Oncotarget|2016Cited by 43
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Luca Boni, Monica Turazza et al.|PLoS ONE|2015Cited by 13
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Nicola Tinari, Eriseld Krasniqi et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Luca Boni, Alessandro Inno et al.|PLoS ONE|2015Cited by 3
Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.Giorgio Mustacchi, Marina Elena Cazzaniga, Monica Giordano et al.|Journal of Clinical Oncology|2017Cited by 0